These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38942217)

  • 1. Right Ventricular Strain Improves the Echocardiographic Diagnosis and Risk Stratification of Transthyretin Cardiac Amyloidosis Among Other Phenotypes of Left Ventricular Hypertrophy.
    Ozbay B; Satyavolu BS; Rearick C; Soman P; Katz WE; Sezer A; Sade LE
    J Am Soc Echocardiogr; 2024 Oct; 37(10):947-959. PubMed ID: 38942217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness.
    Holcman K; Kostkiewicz M; Szot W; Ćmiel B; Mróz K; Stępień A; Graczyk K; Dziewięcka E; Karabinowska-Małocha A; Sachajko Z; Podolec P; Rubiś P
    Int J Cardiovasc Imaging; 2024 Aug; 40(8):1693-1703. PubMed ID: 38856962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional Variation in Technetium Pyrophosphate Uptake in Transthyretin Cardiac Amyloidosis and Impact on Mortality.
    Sperry BW; Vranian MN; Tower-Rader A; Hachamovitch R; Hanna M; Brunken R; Phelan D; Cerqueira MD; Jaber WA
    JACC Cardiovasc Imaging; 2018 Feb; 11(2 Pt 1):234-242. PubMed ID: 28917675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.
    Castaño A; Narotsky DL; Hamid N; Khalique OK; Morgenstern R; DeLuca A; Rubin J; Chiuzan C; Nazif T; Vahl T; George I; Kodali S; Leon MB; Hahn R; Bokhari S; Maurer MS
    Eur Heart J; 2017 Oct; 38(38):2879-2887. PubMed ID: 29019612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Right Ventricular Strain Measured by Two-Dimensional Echocardiography in the Diagnosis of Cardiac Amyloidosis.
    Moñivas Palomero V; Durante-Lopez A; Sanabria MT; Cubero JS; González-Mirelis J; Lopez-Ibor JV; Navarro Rico SM; Krsnik I; Dominguez F; Mingo AM; Hernandez-Perez FJ; Cavero G; Santos SM
    J Am Soc Echocardiogr; 2019 Jul; 32(7):845-853.e1. PubMed ID: 31078369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal Echocardiographic Parameters to Improve the Diagnostic Yield of Tc-99m-Bone Avid Tracer Cardiac Scintigraphy for Transthyretin Cardiac Amyloidosis.
    Cuddy SA; Datar Y; Ovsak G; Saith S; Murphy SP; Bay CP; Haddad M; Lilleness B; Muralidhar V; Pipilas A; Vuong J; Guardino E; Maurer MS; Ruberg FL; Falk RH; Dorbala S
    Circ Cardiovasc Imaging; 2022 Nov; 15(11):e014645. PubMed ID: 36378779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left atrial strain imaging differentiates cardiac amyloidosis and hypertensive heart disease.
    Rausch K; Scalia GM; Sato K; Edwards N; Lam AK; Platts DG; Chan J
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):81-90. PubMed ID: 32728989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
    Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease progression in cardiac morphology and function in heart failure: ATTR cardiac amyloidosis versus hypertensive left ventricular hypertrophy.
    Henein MY; Pilebro B; Lindqvist P
    Heart Vessels; 2022 Sep; 37(9):1562-1569. PubMed ID: 35275264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining echocardiographic predictors of outcome in cardiac amyloidosis by subtype.
    Singulane C; Sun D; Hu Z; Lee L; Sarswat N; Emami Neyestanak M; Patel AR; Lang RM; Addetia K
    Curr Probl Cardiol; 2024 Sep; 49(9):102729. PubMed ID: 38945183
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Tahara N; Lairez O; Endo J; Okada A; Ueda M; Ishii T; Kitano Y; Lee HE; Russo E; Kubo T
    ESC Heart Fail; 2022 Feb; 9(1):251-262. PubMed ID: 34841715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transthyretin Cardiac Amyloidosis as Diagnosed by 99mTc-PYP Scanning in Patients with Acute Heart Failure and Preserved Ejection Fraction.
    Lo Presti S; Horvath SA; Mihos CG; Rajadhyaksha C; McCloskey V; Santana O
    Crit Pathw Cardiol; 2019 Dec; 18(4):195-199. PubMed ID: 31725511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative
    Vijayakumar S; Pabon AR; Clerc OF; Cuddy SAM; Gu Y; Watts C; Sullivan K; Auer B; Kijewski MF; DiCarli MF; Falk RH; Dorbala S
    J Nucl Cardiol; 2024 Sep; 39():102019. PubMed ID: 39128784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal strain of left ventricular basal segments and E/e' ratio differentiate primary cardiac amyloidosis at presentation from hypertensive hypertrophy: an automated function imaging study.
    Schiano-Lomoriello V; Galderisi M; Mele D; Esposito R; Cerciello G; Buonauro A; Della Pepa R; Picardi M; Catalano L; Trimarco B; Pane F
    Echocardiography; 2016 Sep; 33(9):1335-43. PubMed ID: 27277827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.
    Rettl R; Wollenweber T; Duca F; Binder C; Cherouny B; Dachs TM; Camuz Ligios L; Schrutka L; Dalos D; Beitzke D; Loewe C; Badr Eslam R; Kastner J; Hacker M; Bonderman D
    Eur Heart J Cardiovasc Imaging; 2023 Jul; 24(8):1019-1030. PubMed ID: 36881774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive risk stratification of patients with transthyretin amyloidosis.
    Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
    JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echocardiographic score for the screening of cardiac amyloidosis with positive 99m technetium pyrophosphate scintigraphy result.
    Nagai T; Horinouchi H; Hashimoto K; Ichiji T; Yoshioka K; Hashimoto J; Ikari Y
    Echocardiography; 2023 Jul; 40(7):634-641. PubMed ID: 37243310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine 4D Cardiac CT to Identify Concomitant Transthyretin Amyloid Cardiomyopathy in Older Adults with Severe Aortic Stenosis.
    Bernhard B; Leib Z; Dobner S; Demirel C; Caobelli F; Rominger A; Schütze J; Grogg H; Alwan L; Spano G; Boscolo Berto M; Lanz J; Pilgrim T; Windecker S; Stortecky S; Gräni C
    Radiology; 2023 Dec; 309(3):e230425. PubMed ID: 38085082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States.
    Lau ATC; DiDomenico RJ; Kim K
    Int J Cardiol; 2024 Mar; 398():131598. PubMed ID: 37979789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural History and Disease Progression of Early Cardiac Amyloidosis Evaluated by Echocardiography.
    Itzhaki Ben Zadok O; Eisen A; Shapira Y; Monakier D; Iakobishvili Z; Schwartzenberg S; Abelow A; Ofek H; Kazum S; Ben-Avraham B; Hamdan A; Bental T; Sagie A; Kornowski R; Vaturi M
    Am J Cardiol; 2020 Oct; 133():126-133. PubMed ID: 32811652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.